




# Medical Assistance BULLETIN

<b>ISSUE DATE</b> November 8, 2024	<b>EFFECTIVE DATE</b> January 6, 2025	<b>NUMBER</b> *See below
<b>SUBJECT</b>  Prior Authorization of Antifibrotic Respiratory Agents – Pharmacy Services		<b>BY</b>  Sally Kozak Deputy Secretary Office of Medical Assistance Programs

**IMPORTANT REMINDER:** All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: <https://www.pa.gov/en/agencies/dhs/resources/providers/provider-enrollment-information/provider-enrollment-documents.html>.

## **PURPOSE:**

The purpose of this bulletin is to issue updated handbook pages that include the requirements for prior authorization and the type of information needed to evaluate the medical necessity of prescriptions for Antifibrotic Respiratory Agents submitted for prior authorization.

## **SCOPE:**

This bulletin applies to all licensed pharmacies and prescribers enrolled in the Medical Assistance (MA) Program. The guidelines to determine the medical necessity of Antifibrotic Respiratory Agents will be utilized in the fee-for-service and managed care delivery systems. Providers rendering services to MA beneficiaries in the managed care delivery system should address any questions related to the prior authorization of Antifibrotic Respiratory Agents to the appropriate managed care organization.

## **BACKGROUND/DISCUSSION:**

The Department of Human Services (Department) is updating the medical necessity guidelines for Antifibrotic Respiratory Agents to consider therapeutically equivalent brands and generics when evaluating a request for a non-preferred Antifibrotic Respiratory Agent. There are no other changes to the medical necessity guidelines.

*01-25-07	09-25-07	27-25-07	33-25-07
02-25-07	11-25-07	30-25-07	
03-25-07	14-25-07	31-25-07	
08-25-08	24-25-07	32-25-07	

**COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:**

Fee-for-Service Provider Service Center: 1-800-537-8862

Visit the Office of Medical Assistance Programs website at:  
<https://www.pa.gov/en/agencies/dhs/departments-offices/omap-info.html>

The revisions to the guidelines to determine medical necessity of prescriptions for Antifibrotic Respiratory Agents were subject to public review and comment and subsequently approved for implementation by the Department.

**PROCEDURE:**

The procedures for prescribers to request prior authorization of Antifibrotic Respiratory Agents are located in SECTION I of the Prior Authorization of Pharmaceutical Services Handbook. The Department will take into account the elements specified in the clinical review guidelines (which are included in the provider handbook pages in the SECTION II chapter related to Antifibrotic Respiratory Agents) when reviewing the prior authorization request to determine medical necessity.

As set forth in 55 Pa. Code § 1101.67(a), the procedures described in the handbook pages must be followed to ensure appropriate and timely processing of prior authorization requests for drugs and products that require prior authorization.

**ATTACHMENTS:**

Prior Authorization of Pharmaceutical Services Handbook - Updated pages

**RESOURCES:**

Prior Authorization of Pharmaceutical Services Handbook – SECTION I  
Pharmacy Prior Authorization General Requirements

<https://www.pa.gov/en/agencies/dhs/resources/pharmacy-services/pharmacy-prior-authorization-general-requirements.html>

Prior Authorization of Pharmaceutical Services Handbook – SECTION II  
Pharmacy Prior Authorization Guidelines

<https://www.pa.gov/en/agencies/dhs/resources/pharmacy-services/clinical-guidelines.html>

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

**I. Requirements for Prior Authorization of Antifibrotic Respiratory Agents**

**A. Prescriptions That Require Prior Authorization**

All prescriptions for Antifibrotic Respiratory Agents must be prior authorized.

**B. Review of Documentation for Medical Necessity**

In evaluating a request for prior authorization of a prescription for an Antifibrotic Respiratory Agent, the determination of whether the requested prescription is medically necessary will take into account whether the beneficiary:

1. Is prescribed the Antifibrotic Respiratory Agent for the treatment of a diagnosis that is indicated in the U.S. Food and Drug Administration (FDA)-approved package labeling OR a medically accepted indication; **AND**
2. Is age-appropriate according to FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
3. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
4. Is prescribed the Antifibrotic Respiratory Agent by or in consultation with an appropriate specialist (e.g., pulmonologist, rheumatologist, etc.); **AND**
5. Does not have a contraindication to the prescribed drug; **AND**
6. If a current smoker, has documentation of being advised by the prescriber to stop smoking; **AND**
7. For a non-preferred Antifibrotic Respiratory Agent, **one** of the following:
  - a. Has a history of therapeutic failure of or a contraindication or an intolerance to the preferred Antifibrotic Respiratory Agents approved or medically accepted for the beneficiary's indication
  - b. Has a current history (within the past 90 days) of being prescribed the same non-preferred Antifibrotic Respiratory Agent (does not apply to non-preferred brands when the therapeutically equivalent generic is preferred or to non-preferred generics when the therapeutically equivalent brand is preferred).

See the Preferred Drug List (PDL) for the list of preferred Antifibrotic Respiratory Agents at: <https://papdl.com/preferred-drug-list>;

**AND**

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

8. If a prescription for an Antifibrotic Respiratory Agent is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in the Quantity Limits Chapter. The list of drugs that are subject to quantity limits, with accompanying quantity limits, is available at: <https://www.pa.gov/en/agencies/dhs/resources/pharmacy-services/quantity-limits-daily-dose-limits.html>.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

**FOR RENEWALS OF PRIOR AUTHORIZATION FOR AN ANTIFIBROTIC RESPIRATORY AGENT:** The determination of medical necessity of a request for renewal of a prior authorization for an Antifibrotic Respiratory Agent will take into account whether the beneficiary:

1. Is benefitting from the requested drug based on the prescriber's assessment; **AND**
2. Is prescribed a dose that is consistent with FDA-approved package labeling, nationally recognized compendia, or peer-reviewed medical literature; **AND**
3. Is prescribed the Antifibrotic Respiratory Agent by or in consultation with an appropriate specialist (e.g., pulmonologist, rheumatologist, etc.); **AND**
4. Does not have a contraindication to the prescribed drug; **AND**
5. For a non-preferred Antifibrotic Respiratory Agent with a therapeutically equivalent brand or generic that is preferred on the PDL, has a history of therapeutic failure of or a contraindication or an intolerance to the preferred therapeutically equivalent brand or generic that would not be expected to occur with the requested drug.

See the PDL for the list of preferred Antifibrotic Respiratory Agents at: <https://www.papdl.com/preferred-drug-list>;

**AND**

6. If a prescription for an Antifibrotic Respiratory Agent is for a quantity that exceeds the quantity limit, the determination of whether the prescription is medically necessary will also take into account the guidelines set forth in the Quantity Limits Chapter. The list of drugs that are subject to quantity limits, with accompanying quantity limits, is available at: <https://www.pa.gov/en/agencies/dhs/resources/pharmacy-services/quantity-limits-daily-dose-limits.html>.

NOTE: If the beneficiary does not meet the clinical review guidelines listed above but, in the

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary, the request for prior authorization will be approved.

C. Clinical Review Process

Prior authorization personnel will review the request for prior authorization and apply the clinical guidelines in Section B. above to assess the medical necessity of a prescription for an Antifibrotic Respiratory Agent. If the guidelines in Section B. are met, the reviewer will prior authorize the prescription. If the guidelines are not met, the prior authorization request will be referred to a physician reviewer for a medical necessity determination. Such a request for prior authorization will be approved when, in the professional judgment of the physician reviewer, the services are medically necessary to meet the medical needs of the beneficiary.

D. References

1. De Vries-Bouwstra J, Allanore Y, Matucci-Cerinic M, Balbir-Gurman A. Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis. The Journal of Rheumatology May 2019, jrheum.181173; DOI: 10.3899/jrheum.181173.
2. Distler O, Brown KK, Distler JHW, et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clinical and Experimental Rheumatology. 2017 Sep-Oct;35 Suppl 106(4):75-81.
3. Distler O., Highland, KB, Gahlemann M, et.al. (2019). Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease. New England Journal of Medicine, 380(26), 2518–2528. DOI:10.1056/nejmoa1903076
4. Esbriet Package Insert. South San Francisco, CA: Genentech, Inc.; July 2019.
5. Fernández-Codina A, Walker KM, Pope JE. and (2018), Treatment Algorithms for Systemic Sclerosis According to Experts. Arthritis Rheumatol, 70: 1820-1828. doi:10.1002/art.40560
6. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine, 381:1718-27. DOI: 10.1056/NEJMoa1908681
7. King TE. Treatment of idiopathic pulmonary fibrosis. Waltham, MA: UpToDate Inc. Updated January 7, 2020. Accessed July 23, 2020.
8. Johnson SR. New ACR EULAR Guidelines for Systemic Sclerosis Classification. Curr Rheumatol Rep 17, 32 (2015). <https://doi.org/10.1007/s11926-015-0506-3>
9. Ofef Package Insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; March 2020.
10. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guideline for diagnosis and management. American Journal of Respiratory Critical Care Medicine 2011; 183:788.
11. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases 2013;72:1747-1755.
12. Varga J. Clinical manifestations, evaluation, and diagnosis of interstitial lung disease in systemic sclerosis (scleroderma). Waltham, MA: UpToDate Inc. Updated February 7, 2019.

MEDICAL ASSISTANCE HANDBOOK  
PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES

Accessed July 23, 2020.

13. Varga J, Montesi S. Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma). Waltham, MA: UpToDate Inc. Updated October 8, 2019. Accessed July 23, 2020.